Quick summary: AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome .
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome .
Affected product details
Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.
Affected products
Issue
The AstraZeneca COVID-19 Vaccine and COVISHIELD were authorized for use in Canada on February 26, 2021, in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Since the time of authorization, there have been very rare reports of capillary leak syndrome (CLS) following administration of the AstraZeneca COVID-19 Vaccine. Health Canada is working with international regulators and public health authorities to review data and evidence as it becomes available on these very rare events.
What you should do
Additional official information
Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.